Verified Document

Kevzara An Innovative Treatment For Rheumatoid Arthritis Research Paper

Overview of a Recently Approved Drug by the U.S. Food & Drug Administration The exhaustive and lengthy approval process used by the U.S. Food & Drug Administration (FDA) means that when new drugs are released, they are considered sufficiently safe for use by humans as directed by physicians. This approval process, though, also means that just a relatively few new drugs are approved each year, including Kevzara used to treat adult rheumatoid arthritis approved for release on May 22, 2017 (Novel drug approvals, 2017). Given the rapid increase in the elderly demographic in the U.S. in recent years that is projected to continue well into the 21st century (Poterba, 2016), novel treatments for adult rheumatoid arthritis represent important and timely advances in drug therapy. This paper provides a description of Kevazara, including its pharmacodynamics and pharmacokinetic properties as well as an overview of the rheumatoid arthritis disease state for which it is used. In addition, a description concerning what is different about this drug compared to other currently available therapies is followed by a discussion concerning the potential risks associated with this agent and any monitoring parameters that are necessary. Finally, an analysis concerning whether this author would personally prescribe Kevazara or rely on currently available alternatives is followed by a summary of the research and important findings concerning Kevazara in the conclusion.

Description of Kevazara and its pharmacodynamics and pharmacokinetic properties

The newly approved Kevzara was developed for the treatment of adults who suffer from moderate to severe active rheumatoid arthritis following the prescription of at least one other disease-modifying anti-rheumatic drugs which was either not tolerated or failed to produce...

This drug is comprised of an interleukin-6 (IL-6) receptor antagonist (Highlights of prescribing information, 2017). A growing of research indicates that the IL-6 receptor antagonist in particular represents an efficacious intervention for rheumatoid arthritis that cannot be well managed otherwise (Hennigan & Kavanaugh, 2008). In this regard, Hennigan and Kavanaugh (2008) report that, “Efficacy achieved with certain agents [such as] IL-6, a cytokine with effects on numerous cell types, including those involved in the pathogenesis of rheumatoid arthritis” (p. 767).
Overview of the rheumatoid arthritis disease state for which the drug is used

Rheumatoid arthritis is an inflammatory autoimmune disease that causes stiffness, swelling and pain in any of the human joints (typically more than one joint), and if one limb develops the disease, it is probable that the other will as well (Overview of rheumatoid arthritis, 2017). The disease also fatigues sufferers who may also develop fevers but its effects tend to vary in intensity over time in some individuals while others experience a more severe form that can persist for a number of years or even for a entire lifetime (Overview of rheumatoid arthritis, 2017). In fact, the more severe forms of rheumatoid arthritis can result in severe damage to the joints it affects (Overview of rheumatoid arthritis, 2017).

Although the incidence of rheumatoid arthritis, or the number of new cases that are identified each year, has been declining in recent years, there has been a corresponding trends towards onset of the disease at older ages as well (Harris, 2009). At present, the prevalence, or the number of people who actually have rheumatoid arthritis today, is approximately 0.6%…

Sources used in this document:

References

Drug trials snapshot. (2017). U.S. Food & Drug Administration. Retrieved from https://www.fda.gov/Drugs/InformationOnDrugs/ucm562381.htm.

Harris, E. D. (2009, September). The changing dimensions of rheumatoid arthritis and its treatment. Bulletin of the World Health Organization, 81(9), 631.

Hennigan, S. & Kavanaugh, A. (2008, August). Interleukin-6 inhibitors in the treatment of rheumatoid arthritis. Therapeutics and Clinical Risk Management, 4(4), 767–775.

Highlights of prescribing information. (2017). U.S. Food & Drug Administration. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761037s000lbl.pdf.

Novel drug approvals. (2017). U.S. Food & Drug Administration. Retrieved from https://www. fda.gov/drugs/developmentapprovalprocess/druginnovation/ucm537040.htm.

Overview of rheumatoid arthritis. (2017). National Institute of Arthritis and Musculoskeletal and Skin Diseases. Retrieved from https://www.niams.nih.gov/health_info/rheumatic_ disease/rheumatoid_arthritis_ff.asp.

Poterba, J. (2016, January). Economic implications of demographic change. Business Economics, 51(1), 3-5.

Rheumatoid arthritis in depth. (2017). National Center for Complementary and Integrative Health. Retrieved from https://nccih.nih.gov/health/RA/getthefacts.htm.

Rheumatoid arthritis statistics. (2017). Health Union. Retrieved from https://rheumatoidarthritis. net/what-is-ra/ra-statistics/.

Cite this Document:
Copy Bibliography Citation

Related Documents

Rheumatoid Arthritis
Words: 420 Length: 2 Document Type: Case Study

Rheumatoid Arthritis What is happening to the synovium in Arletha's knees and probably her hands as well? In all likelihood, the synovium is inflamed and is not doing its job. The synovium is meant to secret liquid that keeps the joint lubricated. If it's not present or is not doing its job at high efficiency any more, then the joints in the hands and knees will start to become damaged and broken

Rheumatoid Arthritis and the Effect
Words: 1350 Length: 4 Document Type: Term Paper

As well as several reports relating diseases and mood, mental status has also been reported to affect immuno-regulatory systems. Chronic depression or chronic stress conditions lead to immuno-suppressive status and imbalance in corticotrophin-releasing hormone, which induces cancer and hyperthyroidism. It has been reported that depressive states induce suppression of mitogenic reaction in lymphocytes, decreases the number and activity of natural killer cells and decreases the production of interferon." Sadamoto,

Rheumatoid Arthritis Is a Widespread Autoimmune Disease
Words: 1174 Length: 4 Document Type: Research Paper

Rheumatoid arthritis is a widespread autoimmune disease that is linked to progressive disability, socioeconomic costs, systemic complications, and even early death. In addition to having an unknown cause, the disease also has a guarded prognosis. In the past few years, there have been several attempts to understand the pathogenesis of the disease, which have resulted in the creation of new therapeutics with enhanced outcomes (McInnes & Schett, 2011, p.2205). As

Rheumatoid Arthritis & Atherosclerosis: Is
Words: 2681 Length: 10 Document Type: Research Proposal

Though this work focuses specifically on the risk factors of atherosclerosis for RA patients and how to better identify them prior to clinical presentation of atherosclerosis the work is also insightful in that it builds a case for the connection between RA clinical presentations and atherosclerosis, in general. To move forward from this progressive idea is the fact that research has indicated that there is an even greater connection

Rheumatoid Arthritis and Treatment
Words: 1718 Length: 4 Document Type: Essay

Rheumatoid Arthritis: Risks/Benefits of Latest Treatments Rheumatoid arthritis (RA) is a form of arthritis characterized by swelling and tenderness which recent studies have revealed that approximately 1% of grownups suffer from. A common symptom of this disease is symmetric polyarticular inflammation of the synovium, typically of the small joints of the hands (MCP and PIP), wrists and feet. This swelling causes discomfort and difficulty of movement and could result into gradual

Rheumatoid Arthritis
Words: 1456 Length: 5 Document Type: Essay

h2 { color: blue; } Introduction Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by inflammation and progressive destruction of the joints. Understanding its pathophysiology is crucial for developing effective treatment strategies. Immune Dysregulation: RA is mediated by an aberrant immune response involving the activation of T cells and B cells. Dysregulated T cells secrete pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-?)

Sign Up for Unlimited Study Help

Our semester plans gives you unlimited, unrestricted access to our entire library of resources —writing tools, guides, example essays, tutorials, class notes, and more.

Get Started Now